Logo Image

Authors

Roman Fabbricatore
Latest Article

SBRT Plus Nivolumab/Ipilimumab Fails to Improve PFS in Advanced RCC

SBRT plus nivolumab and ipilimumab did not improve PFS vs the dual checkpoint inhibitor regimen alone in advanced RCC.

Ilana Schlam, MD
Latest Article

Trainees Deserve Better Feedback

Feedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.

Fred Saab, MD, FRCS
Sandra Toogood
Latest Article

Novel Frontline Combinations Influence Later-Line Treatment Strategies in SCLC

While progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.

Bhagirathbhai Dholaria, MBBS, of Vanderbilt University Medical Center
Bhagirathbhai Dholaria, MBBS

Bhagirathbhai Dholaria, MBBS, is an associate professor of medicine in the Division of Hematology and Oncology, of the Department of Medicine, at Vanderbilt University Medical Center.

Latest Article

Dr Dholaria on the Mechanism of Action of P-BCMA-ALLO1 in Multiple Myeloma

Bhagirathbhai Dholaria, MBBS, discusses the mechanism of action of P-BCMA-ALLO1 in relapsed/refractory multiple myeloma.

Nicholas Wrigley
Latest Article

Polatuzumab Vedotin Substitution in R-mini-CHOP Does Not Worsen High-Grade Toxicities in DLBCL

Using polatuzumab vedotin instead of vincristine in a reduced-dose regimen of rituximab, cyclophosphamide, doxorubicin, and prednisone was not found to increase grade 3/4 hematologic toxicities, infection risk, or neuropathy in elderly patients with untreated diffuse large B-cell lymphoma.

Patricia L. Lugar, MD, MS
Latest Article

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment

Learn more about the epidemiology, diagnosis, and treatment of advanced systemic mastocytosis in this summary from an expert multidisciplinary case-based discussion.

Jax DiEugenio, OncLive
Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Latest Article

Percutaneous Hepatic Perfusion Could Boost Immunotherapy Response in Metastatic Melanoma

Disrupting liver-driven immune sink by depleting macrophages and preventing T-cell clearance restores responsiveness to immunotherapy in melanoma.

Jori May, MD
Latest Article

Mentoring Oncologists in the Era of Social Distancing

Mentoring is critically important to the development of young academic hematology/oncology trainees.

Quincy Attobrah
Latest Article

SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer

The B7-H3–targeting ADC demonstrated encouraging responses across multiple gynecologic cancers in a phase 1/2 trial.

Candice Schwartz, MD
Latest Article

Biomarkers Drive ICIs in Colon Cancer

December 14, 2020 - Immunotherapy agents have shown efficacy in malignant melanoma, kidney cancer, and non–small cell lung cancer, and investigators are examining the efficacy of checkpoint inhibitors in less immunogenic tumors such as colon cancer, particularly in tumors with high microsatellite instability and deficient mismatch repair genes.

Washington University School of Medicine in St. Louis
Latest Article

Siteman Cancer Center Names New Deputy Director Among Other Leadership Appointments

Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis announces several leadership changes, including a new Deputy Director, Associate Directors of Translational Research and Shared Resources, and a Deputy Associate Director of Shared Resources.

Dietmar Berger, Global Head of Development, Sanofi
Latest Article

Advancing Care in Metastatic Breast Cancer

Sponsored Content by SANOFI

Benjiman Saylor
Latest Article

Subgroup Data From ARANOTE Highlight rPFS Benefit of Darolutamide Plus ADT in Black Patients With mHSPC

Darolutamide plus ADT improved rPFS in Black patients with metastatic hormone-sensitive prostate cancer treated in ARANOTE.

UCLA Health Jonsson Comprehensive Cancer Center
Latest Article

AI May Help Identify Breast Cancers Missed By Mammograms, But Clinical Benefit Remains Uncertain

A UCLA-led review found there is not yet enough real-world evidence to determine whether using AI in routine screening actually reduces the number of breast cancers diagnosed between screenings

UC Davis Health
Latest Article

Cancer Center Earns National Pancreas Foundation Center of Excellence Designation

UC Davis Health joins an elite group recognized for top-tier pancreatic cancer care and research.

Cedars-Sinai Cancer
Latest Article

Missing a Rare Cause of Hereditary Cancer

New research from Cedars-Sinai Cancer investigators could warrant reconsideration of current screening guidelines to include a poorly recognized cause of Lynch syndrome, the most common cause of hereditary colorectal and endometrial cancers.

John D. Shaughnessy, Jr., PhD
Latest Article

Charting a Path for the Integration of Immunotherapy in the Treatment of Multiple Myeloma

Fenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.

Perlmutter Cancer Center at NYU Langone
Latest Article

Ulrich Steidl, MD, PhD, Named Director of Montefiore Einstein Comprehensive Cancer Center

Ulrich Steidl, MD, PhD, has been named director of the Montefiore Einstein Comprehensive Cancer Center and vice president of cancer medicine at Montefiore Einstein.

Paige Britt
Latest Article

Perioperative Enfortumab Vedotin Plus Pembrolizumab Yields Response and Survival Benefits in Cisplatin-Eligible MIBC

Perioperative enfortumab vedotin plus pembrolizumab improved EFS and OS in cisplatin-eligible muscle-invasive bladder cancer.

Rafi Kabarriti, MD
Latest Article

Precision Cancer Care: Preserving Normal Tissue With Proton Therapy

Radiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.

A
A. Kei
A. Keith Stewart, MB, ChB, Mayo Clinic
A. Keith Stewart, MB, ChB, The Mayo Clinic in Phoenix Arizona
A. Ruth He, MD, PhD, Georgetown University Medical Center
Aakanksha Prasad Asija, MD, MPH
Latest Article

When Patients Refuse Treatment for Their Cancer

Quoting statistics seemed to be a refuge to me. The objectivity of the numbers provided a hiding place and a shelter, and they helped me maintain the emotional distance that my profession demanded.

Aarati Rao, MD
Latest Article

A Day In the Life of a Pediatric Oncologist

As a practicing pediatric oncologist at an academic institute, every morning begins with optimism and a quest to win the day.

Aaron C. Logan, MD, PhD, University of California San Francisco
Latest Article

Dr Logan on the Integration of Obe-Cel into Relapsed/Refractory ALL Management

Aaron C. Logan, MD, PhD, discusses the FDA approval of the obe-cel in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Aaron C. Logan, MD, PhD, University of California San Francisco Medical Sciences Building